Pharmaceutical

Travere Therapeutics drug, approved for one rare and de...

Just a few months after the FDA approved sparsentan for IgA nephropathy, Travere...

STAT+: Most of Canada’s public research universities ge...

"It’s critical the schools steward biomedical research in a way that preserves a...

Hospitals that denied emergency abortion broke the law,...

“It was dehumanizing. It was terrifying. It was horrible not to get the care to ...

Expansive investigation into Stanford president’s past ...

An investigation of research co-authored by Stanford President Marc Tessier-Lavi...

Babies born to opioid users have shorter hospital stays...

In the new approach, nurses involve mothers as they evaluate together whether ro...

STAT+: Senators delay start date for possible PBM reforms

Senators drafting reforms to PBMs have delayed their effective date by at least ...

STAT+: Carbon Health blasts a major insurer in rare pub...

Carbon Health blasted health insurer Elevance on Monday for paying it less than ...

In a small new study, scientists working on an AI ‘brai...

Scientists have developed an AI-based system that can "decode" a person's brain ...

STAT+: Pharmalittle: More biotechs are betting on obesi...

A growing number of biotechs are betting on novel mechanisms to treat obesity, h...

Survey: Anti-LGBTQ legislation takes alarming mental-he...

41% of LGBTQ youth seriously considered suicide last year, according to the nati...

STAT+: Astellas acquires Iveric Bio for $5.9B, entering...

Japanese drugmaker Astellas said it would acquire eye drug developer Iveric Bio ...

STAT+: Sam Waksal and Jeremy Levin plot ‘the turnaround...

“I’ve admired the fact that Sam has brought to the market seven separate drugs. ...

Opinion: The apparent poisoning of schoolgirls is just ...

Academic and medical communities in the United States seem uninterested in the h...

STAT+: Beyond Wegovy and Ozempic: Biotechs vie for piec...

You've probably heard of Ozempic and even Mounjaro. But a clutch of startups say...

STAT+: New mega-deal highlights Geisinger’s fall, and r...

Geisinger’s stumbles opened a door for Kaiser Permanente. What does that say abo...

STAT+: Bright Health looks to get out of health insuran...

Bright is looking to sell off the Medicare Advantage plans it manages in Califor...